How Much Does Ozempic Cost in Florida in 2026?

Retail Cash Price for Ozempic Across Florida

The wholesale acquisition cost (WAC) set by Novo Nordisk for Ozempic is $998 per month, and that figure holds across Florida retail chains. Walgreens, CVS, and Publix pharmacies in Miami, Tampa, Orlando, and Jacksonville all price the drug within a few dollars of list. Cash-pay patients receive no automatic discount at the register.

This pricing applies to all four pen strengths: the 0.25 mg/0.5 mg starter pen, the 1 mg pen, and the 2 mg pen. Each box contains four weekly doses, a one-month supply. Novo Nordisk has raised the WAC twice since the original 2017 launch, and the 2026 price reflects a cumulative 18% increase from the initial list of $850 [1]. A 2023 Senate HELP Committee report found that U.S. GLP-1 receptor agonist prices exceed those in peer nations by 300% to 800%, a gap that persists into 2026.

Florida has no state-level drug pricing cap for commercial pharmacy sales. Unlike Colorado and California, which passed GLP-1 affordability legislation in 2025, Florida currently imposes no additional price transparency mandates on manufacturers or PBMs for this drug class [2]. Patients filling at independent pharmacies may occasionally find prices $20 to $40 below chain retail through direct wholesaler purchasing, but such discounts are inconsistent.

GoodRx and RxSaver coupons can reduce the cash price to approximately $850 to $900 in some Florida zip codes. These coupons cannot be combined with insurance or the manufacturer savings card.

Florida Medicaid and Ozempic Coverage

Florida Medicaid covers Ozempic exclusively for type 2 diabetes. Weight management prescriptions are denied. The state's preferred drug list (PDL) includes semaglutide injection under the antidiabetic GLP-1 agonist class, but prior authorization requires a confirmed A1C of 7.0% or higher and documentation that metformin was tried or is contraindicated [3].

The Florida Agency for Health Care Administration (AHCA) administers the Statewide Medicaid Managed Care program through plans like Sunshine Health, Molina, and Humana Healthy Horizons. Each managed care plan applies its own step-therapy protocol on top of the state PDL. Sunshine Health, the largest managed care plan by enrollment, requires failure on or intolerance to metformin plus one additional oral agent before approving Ozempic [4].

Medicaid recipients prescribed Ozempic for type 2 diabetes pay no copay under Florida's fee-for-service pathway or managed care. The practical barrier is prior authorization turnaround: AHCA data from fiscal year 2024-2025 showed a median PA decision time of 72 hours, though 15% of requests took longer than seven business days [5].

For weight loss specifically, Florida Medicaid does not cover any GLP-1 receptor agonist. This includes Wegovy, the semaglutide 2.4 mg formulation FDA-approved for chronic weight management. The 2025 Florida legislative session considered SB 1240, which would have added anti-obesity medications to Medicaid formularies. That bill died in committee.

Commercial Insurance Coverage in Florida

Most employer-sponsored and marketplace plans in Florida cover Ozempic for type 2 diabetes with prior authorization. Blue Cross Blue Shield of Florida (Florida Blue), Aetna, UnitedHealthcare, and Cigna all list semaglutide injection on their commercial formularies, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand) [6].

Copays vary widely. A Tier 3 placement on a Florida Blue PPO plan might yield a $60 to $90 copay per fill. A Tier 4 placement on a high-deductible Cigna plan could mean $150 to $250 before the deductible is met. Coinsurance models (common in Marketplace Silver plans) charge 25% to 40% of the negotiated rate, which can exceed $200 per month.

Coverage for off-label weight loss use is rare in Florida's commercial market. UnitedHealthcare's 2026 commercial policy bulletin explicitly excludes Ozempic for obesity, directing those patients to Wegovy instead. Wegovy itself faces separate coverage criteria requiring a BMI of 30 or higher (or 27 with a weight-related comorbidity) plus documentation of a structured diet and exercise program lasting at least six months [7].

The SUSTAIN clinical trial program established the efficacy data that underpins these coverage decisions. SUSTAIN-7 (N=1,201) demonstrated that semaglutide 0.5 mg and 1.0 mg produced superior A1C reductions compared to dulaglutide at 40 weeks: -1.5% versus -1.1% for the 0.5 mg comparison and -1.8% versus -1.4% for the 1.0 mg comparison [8]. These results, along with the broader SUSTAIN program, form the clinical foundation insurers reference when writing coverage criteria.

The Novo Nordisk Savings Card: How It Works in Florida

Commercially insured patients can use the Novo Nordisk savings card to pay as little as $25 per 28-day Ozempic fill for up to 24 months. The card covers the difference between the patient's copay or coinsurance and the $25 floor, up to a maximum benefit of $150 per fill or $1,800 per calendar year.

Eligibility has two hard requirements: the patient must carry commercial insurance (not Medicare, Medicaid, Tricare, or VA), and the insurance must cover Ozempic. Uninsured patients do not qualify for the savings card but may apply to the separate Novo Nordisk Patient Assistance Program (PAP), which provides free medication to households earning below 400% of the federal poverty level [9].

In practice, the savings card works at any Florida pharmacy that accepts electronic copay cards. The pharmacist runs the prescription through insurance first, then applies the savings card as a secondary claim. If the insurance copay is $90, the patient pays $25 and Novo Nordisk reimburses the pharmacy $65.

One common Florida-specific friction point: some Publix and Winn-Dixie pharmacies have reported delays processing the electronic secondary claim, requiring a manual override. Patients can call the number on the card (1-877-304-6855) for real-time pharmacy support.

The card resets annually on January 1. Patients approaching the $1,800 annual cap in October or November may face full copay exposure for the remainder of the year.

Compounded Semaglutide in Florida: Legality, Pricing, and Oversight

Compounded semaglutide is legal in Florida through 503A compounding pharmacies operating under the Florida Board of Pharmacy. These pharmacies compound patient-specific prescriptions based on a valid provider-patient relationship. The typical price for compounded semaglutide in Florida is approximately $199 per month, roughly 80% below brand-name Ozempic.

The legal framework rests on Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding of FDA-approved active ingredients when a commercial shortage exists or when a prescriber determines that a compounded preparation is medically necessary for an individual patient [10]. The FDA placed semaglutide on its drug shortage list intermittently between 2022 and 2025, which expanded compounding access during those periods.

As of May 2026, semaglutide supply has largely stabilized. The FDA removed it from the shortage list in February 2026. This means 503A compounding of semaglutide now requires individual medical necessity documentation from the prescribing provider, not just a blanket shortage justification. Florida 503A pharmacies that continue compounding must maintain records showing patient-specific prescriptions and cannot produce bulk "office stock" for clinics without 503B outsourcing facility registration [11].

Florida's Board of Pharmacy conducts inspections of 503A compounding operations. In 2025, the Board issued four warning letters and one cease-and-desist order to Florida-based compounding pharmacies producing semaglutide preparations that failed potency testing or lacked adequate sterility assurance protocols [12]. Patients considering compounded semaglutide should verify that their pharmacy holds a current Florida compounding license and can provide a certificate of analysis for each batch.

Dr. Caroline Apovian, a professor of medicine at Harvard Medical School, has stated: "Compounded GLP-1 medications fill a real access gap for patients who cannot afford brand-name drugs, but quality control varies enormously between pharmacies. Patients should ask for potency and sterility testing documentation before their first injection" [13].

Telehealth Prescribing of Ozempic in Florida

Florida law permits telehealth prescribing of Ozempic and compounded semaglutide. The Florida Telehealth Act (F.S. 456.47) authorizes licensed physicians, nurse practitioners, and physician assistants to prescribe controlled and non-controlled medications via synchronous audio-video encounters. Semaglutide is not a controlled substance, so it faces no additional telehealth prescribing restrictions in the state [14].

Multiple telehealth platforms operate in Florida and prescribe semaglutide. HealthRX offers physician-supervised semaglutide treatment with ongoing metabolic monitoring. Patients complete a medical intake, undergo a synchronous video consultation, and receive prescriptions sent to a licensed Florida pharmacy or a partnered 503A compounding pharmacy.

The Florida Board of Medicine requires that telehealth providers establish a legitimate provider-patient relationship before prescribing. A questionnaire-only "consultation" without real-time interaction does not meet this standard. In 2025, the Board disciplined three Florida-licensed providers for prescribing GLP-1 agonists based solely on asynchronous intake forms without any synchronous evaluation [15].

Telehealth visits for Ozempic in Florida typically cost $99 to $199 for the initial consultation and $49 to $99 for monthly follow-ups. Some platforms bundle the consultation fee with the medication cost, particularly when dispensing compounded semaglutide.

Cost Comparison: All Florida Semaglutide Options

A side-by-side view clarifies the real out-of-pocket exposure for Florida patients across every access pathway.

Brand Ozempic, cash pay: $998 per month. No insurance involvement. Available at all retail pharmacies. Full Novo Nordisk product with lot-level FDA oversight.

Brand Ozempic, commercial insurance: $25 to $250 per month depending on formulary tier, deductible status, and savings card eligibility. Requires prior authorization for type 2 diabetes indication.

Brand Ozempic, Florida Medicaid: $0 copay if approved for type 2 diabetes. Not available for weight management.

Compounded semaglutide (503A): approximately $199 per month. Requires a valid prescription and patient-specific compounding order. Not covered by insurance. Quality depends on pharmacy oversight.

Wegovy (semaglutide 2.4 mg for weight management): $1,349 per month cash; commercial coverage increasingly available but with strict criteria. Separate from Ozempic and prescribed at a higher dose.

The American Diabetes Association's 2024 Standards of Care recommends GLP-1 receptor agonists as second-line therapy after metformin for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, citing the SELECT trial (N=17,604), which demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg versus placebo over a median 39.8 months of follow-up [16].

Strategies to Lower Your Ozempic Cost in Florida

Start with insurance. If you have commercial coverage and a type 2 diabetes diagnosis, file the prior authorization. Your provider's office handles the clinical documentation. Median approval time across Florida commercial plans is five business days.

Apply the savings card immediately after insurance approval. Even a $60 copay drops to $25. The card is free to activate at ozempic.com or by calling 1-877-304-6855.

If you are uninsured and earn below 400% FPL ($62,400 for a single individual in 2026), apply to the Novo Nordisk Patient Assistance Program. Approval typically takes two to three weeks and provides free brand-name Ozempic shipped to your provider's office [17].

Consider compounded semaglutide if brand-name cost remains prohibitive. Verify the pharmacy's Florida Board of Pharmacy license, ask for the most recent certificate of analysis, and confirm the preparation is a sterile injectable compounded under 503A standards.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has noted: "Cost remains the single biggest barrier to GLP-1 therapy adherence. Patients who stop treatment due to cost lose the metabolic gains within weeks" [18].

Do not split pens or share multi-dose pens. The Ozempic pen is designed for single-patient use across its four doses, and sharing introduces contamination and dosing accuracy risks. The FDA labeling explicitly warns against pen sharing even when needles are changed [1].